Compare Wahed FTSE USA Shariah ETF (HLAL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Incyte Corporation — how do they compare? Wahed FTSE USA Shariah ETF trades at $71, while Incyte Corporation trades at $116 (market cap $23.44B). Which is the better fit depends on your goals.
| HLAL | INCY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $118.52 |
52-Week Low | $54.05 | $68.90 |
Market Cap | — | $23.44B |
Enterprise Value | — | $19.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock faces resistance at $71 and support at $70. Key financial ratios including P/E, P/S, and ROE are unavailable in the current dataset, limiting fundamental assessment. A small dividend of $0.02 is scheduled for June 2026.
The outlook remains cautious due to weak technical momentum and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to validate valuation. Primary risks include market volatility and lack of recent business updates. Analyst sentiment appears neutral to bearish given the technical configuration.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
